Literature DB >> 1260974

Blood pressure and plasma angiotensin II concentration after renal artery constriction and angiotensin infusion in the dog. (5-Isoleucine)angiotensin II and its breakdown fragments in dog blood.

A M Caravaggi, G Bianchi, J J Brown, A F Lever, J J Morton, J D Powell-Jackson, J I Robertson, P F Semple.   

Abstract

We measured arterial plasma angiotensin II concentration, renal blood flow, and arterial blood pressure in six conscious dogs during intravenous infusion of angiotensin II (5, 10, and 20 ng/kg per min). The same measurements were made on a different occasion in the same six animals, while they were conscious, before and during constriction of a main renal artery. Arterial blood pressure and plasma angiotensin II rose and renal blood flow decreased in both experiments. The similarity of regressions for plasma angiotensin II concentration and arterial blood pressure in the two experiments strongly suggests that the rise of circulating angiotensin II after renal artery constriction is sufficient to account for the hypertension by its direct pressor action. As discussed, a different mechanism seems likely to be involved in the later stages of renal hypertension. Angiotensin II is more likely to be in the 5-isoleucine form than in the 5-valine form in the dog. In contrast to the rat, plasma concentrations of the heptapeptide (angiotensin III), hexapeptide, and pentapeptide fragments of angiotensin II are low in the dog.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1260974     DOI: 10.1161/01.res.38.4.315

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  6 in total

1.  The half-lives of angiotensin II, angiotensin II-amide, angiotensin III, Sar1-Ala8-angiotensin II and renin in the circulatory system of the rat.

Authors:  S A Al-Merani; D P Brooks; B J Chapman; K A Munday
Journal:  J Physiol       Date:  1978-05       Impact factor: 5.182

2.  Inhibitors of the renin-angiotensin system in experimental hypertension, with a note on the measurement of angiotensin I, II and III during infusion of converting-enzyme inhibitor.

Authors:  J J Morton; J Casals-Stenzel; A F Lever; J A Millar; A J Riegger; M Tree
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

3.  Intrarenal angiotensin II and angiotensinogen augmentation in chronic angiotensin II-infused mice.

Authors:  Romer A Gonzalez-Villalobos; Dale M Seth; Ryousuke Satou; Heather Horton; Naro Ohashi; Kayoko Miyata; Akemi Katsurada; Duy V Tran; Hiroyuki Kobori; L G Navar
Journal:  Am J Physiol Renal Physiol       Date:  2008-06-25

4.  Captopril in renovascular hypertension: long-term use in predicting surgical outcome.

Authors:  A B Atkinson; J J Brown; A M Cumming; R Fraser; A F Lever; B J Leckie; J J Morton; J I Robertson
Journal:  Br Med J (Clin Res Ed)       Date:  1982-03-06

5.  Renal artery stenosis with severe hypertension. A rare case with detailed assessment of renin-angiotensin system before and after development of lesion.

Authors:  A Mackay; A M Cumming
Journal:  Br Heart J       Date:  1979-10

6.  Reversal by angiotensins II and III of the effects of converting enzyme inhibition on renal electrolyte excretion in rats.

Authors:  P J Harris; J O Munro
Journal:  J Physiol       Date:  1984-06       Impact factor: 5.182

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.